According to Research and Markets, the global market for Fc and glycoengineered antibodies is projected to be worth US$38.8 billion in 2024. Over the next decade, the growth in opportunities for drug developers is expected to be driven by an increasing patient population and rising demand for these

As antibody-drug development accelerates, ensuring consistent binding affinity, stability, and specificity is critical to improving treatment outcomes. Recent advances in antibody sequencing, artificial intelligence, and high-throughput screening have bolstered efforts to produce reliable antibody candidates more efficiently.

This year’s Nobel prize in chemistry was awarded last month for using computationally designing novel proteins and predicting structures! The first half of the prize was awarded to John Jumper and Demis Hassabis, who developed AlphaFold, an artificial intelligence (AI) program that can predict a protein’s shape and function from its chemical sequence.

Bispecific antibodies are rapidly transforming the therapeutic landscape, especially in oncology and autoimmune diseases. Such recombinant molecules can bind to two different antigens at the same time, offering greater specificity in targeting disease pathways. Since their introduction, the area of bispecifics has held tremendous promise in oncological cancers like multiple myeloma and lymphomas.

These past few weeks, several antibody drug startups have progressed from the pre-seed stage to final funding rounds. In the pre-seed stage, the focus is on early research, often funded by founders, grants, or angel investors. As the company progresses to the seed stage, it seeks additional funding to validate its scientific concept and develop initial prototypes, attracting early-stage venture capital.

This month provided not just one, but two FDA approvals for antibody drugs treating patients with paroxysmal nocturnal hemoglobinuria (PNH)!